Medicines Co. picks up three EU approvals; Biogen, Samsung press on Remicade biosim;

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Story | Follow @FierceBiotech

@JohnCFierce: Big part of the $NVS/Aduro deal is that Dana Farber's Glenn Dranoff was tapped to run a new IO R&D group. More | Follow @JohnCFierce

@DamianFierce: Success for Sovaldi, a win for Vimizim and a eulogyto for Blincyto. #FierceMadness continues. More | Follow @DamianFierce

> The Medicines Company ($MDCO) picked up a trio of European approvals, winning nods for cangrelor, an anticoagulant rejected by the FDA last year; oritavancin, an antibiotic approved in the U.S. last year as Orbactiv; and Raplixa, a surgical sealant under FDA review. More

> The European Medicines Agency has accepted Biogen ($BIIB) and Samsung's application for a biosimilar of Johnson & Johnson's ($JNJ) blockbuster autoimmune treatment Remicade, setting the stage for an approval this year. News

> Israeli biotech Can-Fite's psoriasis drug failed to meet its primary endpoint in a Phase II/III study, sending the company's shares down by more than 50% on the Tel Aviv exchange. Item

Medical Device News

@FierceMedDev: Zimmer to divest three businesses to satisfy EU regulators in Biomet acquisition. Report | Follow @FierceMedDev

@VarunSaxena2: Outgoing FDA commissioner: Regulation, when done right, not a roadblock | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: Horizon scoops up Hyperion and its rare disease portfolio for $1.1B. FiercePharma news | Follow @EmilyWFierce

> FDA taking 'very light touch' in smartphone and digital device regulation. Story

> Nanorobot shows promise as humidity sensor thanks to use of bacterial spore. Article

> Devicemaker, CEO, take on FDA over 'free speech' of sales pitch. More

Pharma News

@FiercePharma: Report: Pet owners clueless about obesity in their cats and dogs. FierceAnimalHealth item | Follow @FiercePharma

@EricPFierce: ICYMI: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Report | Follow @EricPFierce

@CarlyHFierce: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @CarlyHFierce

> Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015. Report

> Horizon scoops up Hyperion and its rare disease portfolio for $1.1B. Article

Animal Health News

> Jaguar Animal Health eyes a second run at IPO. Report

> Critics say White House plan to combat antibiotic resistance falls 'woefully short.' More

> Report: Pet owners clueless about obesity in their cats and dogs. Item

> Gene testing and animal safety services drive double-digit growth at Neogen. Article

> U.K. scientists discover parasite protects cows against deadly East Coast fever. Story

Biotech IT News

> George Church backs online platform for open sharing of personal data. Report

> Committee clips the wings of Europe's controversial $1B brain project. Article

> Emerging markets tipped to push drug safety software market past $150M. Story

> NIH backs database of rare pediatric genetic disorders. Item

> 100,000 Genomes Project taps Big Pharma dream team for data crunching skills. More

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.